Clinical value of circulating miR-6861-5p in the diagnosis and treatment of breast cancer
-
摘要:
目的 研究miR-6861-5p在乳腺癌患者血清中的表达，并探讨miR-6861-5p表达在乳腺癌患者临床诊治中的价值。 方法 通过实时荧光定量PCR法（RT-qPCR）检测2012年1月至2015年6月山东省德州市第二人民医院112例乳腺癌患者、37例乳腺良性病变和53例健康女性血清miR-6861-5p相对表达量，分析血清miR-6861-5p表达与乳腺癌患者临床病理和术后复发之间的关系，并探讨其表达对乳腺癌的临床诊断价值。 结果 乳腺癌患者血清miR-6861-5p相对表达量为（7.99±1.63），显著高于良性病变患者（6.45±1.06）（P＜0.05）和健康研究对象（6.43±1.28）（P＜0.05）；血清miR-6861-5p表达与乳腺癌患者淋巴结转移、肿瘤组织ER、PR和HER-2表达、TNM分期、分子分型以及组织学分期显著相关（均P＜0.05）；肿瘤切除后乳腺癌患者血清miR-6861-5p表达量显著降低；治疗前血清miR-6861-5p诊断乳腺癌的敏感度和特异度分别为69.6%和77.8%，且与乳腺癌患者术后复发率有关。 结论 miR-6861-5p在乳腺癌患者血清中表达上调，是术前乳腺癌诊断、肿瘤分期、癌细胞转移和术后监测乳腺癌复发的潜在生物标志物。 -
关键词:
- miR-6861-5p /
- 乳腺癌 /
- 临床病理 /
- 血清
Abstract:Objective This study was conducted to detect circulating miR-6861-5p and evaluate its diagnositic value in the diagnosis and treatment of breast cancer. Methods MiR-6861-5p expression was detected by RT-qPCR in 112 patients with breast cancer enrolled in the Second People Hospital of Dezhou from January 2012 to June 2015, with 37 patients diagnosed with benign breast lesions, and 53 healthy people. The relationship between circulating miR-6861-5p and clinicopathologic features and the postoperative recurrence of breast cancer was analyzed to explore the diagnostic value of circulating miR-6861-5p in patients with breast cancer. Results Circulating miR-6861-5p expression was significantly higher in patients with breast cancer (7.99±1.63) than in patients with benign breast lesions (6.45±1.06) and healthy people (6.43±1.28) (p < 0.05). There was a significant correlation between circulating miR- 6861-5p and lymph node metastasis, estrogen receptor, progesterone receptor, HER-2 expression, TNM staging, molecular typing, and histological staging in patients with breast cancer (p < 0.05). Circulating miR-6861-5p significantly decreased after tumor resection (p < 0.05) and was significantly correlated with the recurrence rates after treatment. The sensitivity and specificity of diagnosis in breast cancer by detecting circulating miR-6861-5p were 69.6% and 77.8%, respectively. Conclusions There is high expression of circulating miR-6861-5p in breast cancer, which may serve as useful diagnostic, staging, cancer cell metastasis, and postoperative recurrence biomarker in patients with breast cancer. -
Key words:
- miR-6861-5p /
- breast cancer /
- clinicopathologic features /
- serum
-
表 1 3组研究对象一般资料比较 例
表 2 血清miR-6861-5p表达与乳腺癌临床病理资料的关系 例（%）
-
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. Ca A Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338 [2] 易琳, 刘兴明, 林丁, 等.血清CA153、CA125、CEA联合检测在乳腺癌诊断中的价值[J].重庆医科大学学报, 2012, 37(9):802-805. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_cqykdxxb201209014 [3] Xia J, Shi J, Wang P, et al. Tumour‐Associated autoantibodies as diagnostic biomarkers for breast cancer: A systematic review and meta-analysis[J]. Scand J Immunol, 2016, 83(6):393-408. doi: 10.1111/sji.2016.83.issue-6 [4] 张帆, 崔庆华.microRNA与人类疾病关系研究中的生物信息学方法和资源[J].生理科学进展, 2016, 47(3):203-209. http://www.cnki.com.cn/Article/CJFDTotal-SLKZ201603008.htm [5] Kang L, Yang C, Song Y, et al. MicroRNA-23a-3p promotes the development of osteoarthritis by directly targeting SMAD3 in chondrocytes[J]. Biochem Biophys Res Commun, 2016, 478(1):467-473. doi: 10.1016/j.bbrc.2016.06.071 [6] 刘宁, 徐波, 梁寒, 等.miRNA和恶性肿瘤研究进展[J].中国肿瘤临床, 2010, 37(7):416-420. http://manu21.magtech.com.cn/cjco/CN/abstract/abstract9654.shtml [7] Li W, Liu C, Zhao C, et al. Downregulation of β3 integrin by miR-30a-5p modulates cell adhesion and invasion by interrupting Erk/Ets 1 network in triple-negative breast cancer[J]. Int J Oncol, 2016, 48(3): 151-159. http://www.ncbi.nlm.nih.gov/pubmed/26781040 [8] Li W F, Dai H, Ou Q, et al. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.[J]. Tumor Biology, 2016, 37(5):5885-5895. doi: 10.1007/s13277-015-4456-1 [9] 张庆勇, 李乾元, 罗春华.肿瘤标志物外周血microRNA的研究进展[J].细胞与分子免疫学杂志, 2015, 31(3):419-421. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zgpwjcylczz201209031 [10] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30):10513. doi: 10.1073/pnas.0804549105 [11] Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer, 2013, 132 (7):1602-1612. doi: 10.1002/ijc.27799 [12] Shen J, Hu Q, Schrauder M, et al. Circulating miR-148b and miR-133a as biomarkers for breast cancer detection[J]. Oncotarget, 2014, 5(14):5284-5294. http://europepmc.org/abstract/MED/25051376 [13] 魏倩, 张鹏.乳腺癌患者癌组织、血清miR-17-5p水平变化及意义[J].山东医药, 2015, 55(16):54-55. doi: 10.3969/j.issn.1002-266X.2015.16.27 [14] Sochor M, Basova P, Pesta M, et al. Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum[J]. BMC Cancer, 2014, 14(1):448. doi: 10.1186/1471-2407-14-448 [15] 典辉, 库无非, 何明长.miR-127-3P在乳腺癌患者中的表达及意义[J].肿瘤学杂志, 2017, 23(7):639-642. doi: 10.11735/j.issn.1671-170X.2017.07.B017 [16] 钟婧, 周伟民, 马志红, 等.微小RNA-21在乳腺癌患者血清中的表达及其与临床病理特征的关系[J].中华实验外科杂志, 2015, 32(1): 157-159. http://d.old.wanfangdata.com.cn/Periodical/zhsywk201501057 [17] Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage[J]. Cancer Sci, 2016, 107(3):326-334. doi: 10.1111/cas.12880 [18] 左婷婷, 陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床, 2016, 43(14):639-642. doi: 10.3969/j.issn.1000-8179.2016.14.503 [19] 赵毅, 邓鑫.乳腺癌分子分型与治疗策略[J].中国实用外科杂志, 2015, 35(7):704-708. http://special.medlive.cn/special/12 [20] 李双, 范红敏, 肖菲菲, 等.不同分子分型及临床病理特征与乳腺癌术后患者预后的关系[J].临床与实验病理学杂志, 2016, 32(1):39-44. http://d.old.wanfangdata.com.cn/Periodical/lcysyblxzz201601009 -
下载:
点击查看大图
图(4) / 表(2)
计量
- 文章访问数: 72
- HTML全文浏览量: 0
- PDF下载量: 2
- 被引次数: 0
